Wakeling AE - Search Results

1

ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness.

Thompson EW, Katz D, Shima TB, Wakeling AE, Lippman ME, Dickson RB. Thompson EW, et al. Among authors: wakeling ae. Cancer Res. 1989 Dec 15;49(24 Pt 1):6929-34. Cancer Res. 1989. PMID: 2582435

2

MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780.

Brünner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME, Clarke R. Brünner N, et al. Among authors: wakeling ae. Cancer Res. 1993 Jul 15;53(14):3229-32. Cancer Res. 1993. PMID: 8324732

3

Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle.

Musgrove EA, Wakeling AE, Sutherland RL. Musgrove EA, et al. Among authors: wakeling ae. Cancer Res. 1989 May 1;49(9):2398-404. Cancer Res. 1989. PMID: 2706627

4

ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen.

Howell A, Osborne CK, Morris C, Wakeling AE. Howell A, et al. Among authors: wakeling ae. Cancer. 2000 Aug 15;89(4):817-25. doi: 10.1002/1097-0142(20000815)89:4<817::aid-cncr14>3.0.co;2-6. Cancer. 2000. PMID: 10951345

5

The pure antiestrogen ICI 182,780 binds to a high-affinity site distinct from the estrogen receptor.

Parisot JP, Hu XF, Sutherland RL, Wakeling A, Zalcberg JR, DeLuise M. Parisot JP, et al. Int J Cancer. 1995 Aug 9;62(4):480-4. doi: 10.1002/ijc.2910620420. Int J Cancer. 1995. PMID: 7635575

6

Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780.

Hu XF, Veroni M, De Luise M, Wakeling A, Sutherland R, Watts CK, Zalcberg JR. Hu XF, et al. Int J Cancer. 1993 Nov 11;55(5):873-6. doi: 10.1002/ijc.2910550529. Int J Cancer. 1993. PMID: 8244585

7

A potent specific pure antiestrogen with clinical potential.

Wakeling AE, Dukes M, Bowler J. Wakeling AE, et al. Cancer Res. 1991 Aug 1;51(15):3867-73. Cancer Res. 1991. PMID: 1855205

8

Differential effects of estrogen, tamoxifen and the pure antiestrogen ICI 182,780 in human drug-resistant leukemia cell lines.

Zalcberg JR, Hu XF, Ching M, Wakeling A, Wall DM, Marschner IC, de Luise M. Zalcberg JR, et al. Cancer Chemother Pharmacol. 1993;33(2):123-9. doi: 10.1007/BF00685329. Cancer Chemother Pharmacol. 1993. PMID: 7903222

9

The future of new pure antiestrogens in clinical breast cancer.

Wakeling AE. Wakeling AE. Breast Cancer Res Treat. 1993;25(1):1-9. doi: 10.1007/BF00662395. Breast Cancer Res Treat. 1993. PMID: 8518404 Review.

10

Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.

Robertson JF, Nicholson RI, Bundred NJ, Anderson E, Rayter Z, Dowsett M, Fox JN, Gee JM, Webster A, Wakeling AE, Morris C, Dixon M. Robertson JF, et al. Among authors: wakeling ae. Cancer Res. 2001 Sep 15;61(18):6739-46. Cancer Res. 2001. PMID: 11559545 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

126 results

Search Page

Filters